Education
About Us
Working with TipRanks
Follow Us
David Hyman Insider Profile
4 Followers
David Hyman, Chief Financial Officer at Rakovina Therapeutics Inc, holds 315.00K shares in Rakovina Therapeutics Inc (Ticker: TSE:RKV), holds 40.00K shares in Medicenna Therapeutics Corp (Ticker: TSE:MDNA). Most recently, David Hyman ― shares of Rakovina Therapeutics Inc on ― for an estimated value of ―.
David Hyman has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that David Hyman holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by David Hyman
David Hyman's Trading History
Rakovina Therapeutics Inc
―
Chief Financial Officer
―
C$176.40K
Medicenna Therapeutics Corp
Jan 11, 2025
Chief Financial Officer
Informative Buy
29.00K
C$34.40K
List of latest transactions for each holding click on a transaction to see David Hyman's performance on stock
You May Also Like
David Hyman insider profile FAQ
What is the percentage of profitable transactions made by David Hyman?
The percentage of profitable transactions made by David Hyman is ―.
What is the average return per transaction made by David Hyman?
The average return per transaction made by David Hyman is ―.
What stocks does David Hyman hold?
David Hyman holds: TSE:RKV, TSE:MDNA stocks.
What was David Hyman’s latest transaction?
David Hyman latest transaction was an Uninformative Buy of ―.
What was David Hyman's most profitable transaction?
David Hyman’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is David Hyman's role in Rakovina Therapeutics Inc?
David Hyman's role in Rakovina Therapeutics Inc is Chief Financial Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.